Letters to the Editor
Vol. 5 No. 4 (2026)
https://doi.org/10.4081/btvb.2026.592

Antithrombotic therapy in retinal vein occlusion: many questions, few evidence-based answers

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 19 October 2026
0
Views
0
Downloads
anticoagulants, retinal vein occlusion, venous thromboembolism

Authors

Emanuele Valeriani
emanuele.valeriani@uniroma1.it
Department of Internal Medicine, Endocrine and Metabolic Sciences, and Infectious Diseases, Umberto I Hospital of Rome, Italy.
Paolo Gresele
Department of Medicine and Surgery, University of Perugia, Italy.
Francesco Paciullo
Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
Pasquale Pignatelli
Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Domenico Prisco
Department of Experimental and Clinical Medicine, University of Florence, Italy.

Retinal vein occlusion (RVO) is a common cause of visual impairment, yet considerable uncertainty remains regarding the role of systemic anticoagulation and, if prescribed, its optimal regimen.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1.Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9. DOI: https://doi.org/10.1016/j.ophtha.2009.07.017
2.Paciullo F, Valeriani E, Porfidia A, et al. Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus 2022;20:341-7.
3.Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res 2010;125:137-41. DOI: https://doi.org/10.1016/j.thromres.2009.05.007
4.Farahvash MS, Moghaddam MM, Moghimi S, et al. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 2008;43:79-83. DOI: https://doi.org/10.3129/i07-190
5.Farahvash MS, Moradimogadam M, Farahvash MM, et al. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008;11:418-22.
6.Valeriani E, Paciullo F, Porfidia A, et al. Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis. J Thromb Haemost 2023;21:284-93. DOI: https://doi.org/10.1016/j.jtha.2022.10.003
7.Christiansen CB, Torp-Pedersen C, Olesen JB, et al. Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. BMC Cardiovasc Disord 2018;18:91. DOI: https://doi.org/10.1186/s12872-018-0825-1
8.Rim TH, Oh J, Lee CS, et al. Evaluation of the association between retinal vein occlusion and the risk of atrial fibrillation development: a 12 year, retrospective nationwide cohort study. Sci Rep 2016;6:34708. DOI: https://doi.org/10.1038/srep34708
9.Park SJ, Lee E, Lee K, et al. Efficacy and safety of non-vitamin K-antagonist oral anticoagulants for retinal vascular diseases in patients with atrial fibrillation: Korean cohort study. Sci Rep 2020;10:4577. DOI: https://doi.org/10.1038/s41598-020-61609-8
10.Russell MW, Shukla P, Singh RP, et al. Anticoagulation therapy and influence on retinal vein occlusion and intraocular bleeding risk across a large US national database. Ophthalmic Surg Lasers Imaging Retina 2025;56:520-4. DOI: https://doi.org/10.3928/23258160-20250523-01

Ethics Approval

not applicable

CRediT authorship contribution

Drafting of the manuscript: EV, PP, DP; Critical revision of the manuscript for important intellectual content: PG, FP.

Supporting Agencies

none

Data Availability Statement

Not applicable.

How to Cite



1.
Valeriani E, Gresele P, Paciullo F, Pignatelli P, Prisco D. Antithrombotic therapy in retinal vein occlusion: many questions, few evidence-based answers. Bleeding Thromb Vasc Biol [Internet]. 2026 Oct. 19 [cited 2026 Oct. 20];5(4). Available from: https://www.btvb.org/btvb/article/view/592
Copyright (c) 2026 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.